drugset / Trial / NCT02429102

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects

NCT02429102

Phase 1 Completed 135 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-8554 in healthy Caucasian subjects.

Timeline

Start
2015-04
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule

Indications

No indication recorded.